Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey Buys 30,000 Shares

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey acquired 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $4.39 per share, with a total value of $131,700.00. Following the completion of the transaction, the director now directly owns 240,113 shares in the company, valued at approximately $1,054,096.07. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Marc Duey also recently made the following trade(s):

• On Monday, October 14th, Marc Duey purchased 190 shares of Aprea Therapeutics stock. The shares were bought at an average cost of $2.58 per share, with a total value of $490.20.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock traded up $0.25 during trading on Thursday, reaching $3.75. The company had a trading volume of 25,484 shares, compared to its average volume of 19,916. Aprea Therapeutics, Inc. has a 12-month low of $2.15 and a 12-month high of $8.85. The stock’s 50 day moving average price is $3.16 and its two-hundred day moving average price is $4.19. The firm has a market capitalization of $20.36 million, a price-to-earnings ratio of -1.13 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Monday, August 12th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05. The firm had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. As a group, research analysts expect that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest holding. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 34.19% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on APRE shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research note on Monday, August 12th. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.